In 2011, I was diagnosed with stage 2 breast cancer. After going through therapy, I was declared in remission. However, it wasn’t long before my numbers were up again. At that point, I decided to have a double mastectomy and breast reconstruction. This process was an arduous one, both physically and mentally, for myself and for my family. I was in remission for two years following the surgeries, but ultimately ended up back in the hospital.

In 2015, my cancer came back. It metastasized and found its way into my liver and bones, and I found myself facing the difficulties of obtaining affordable healthcare in America.

Pfizer’s blockbuster cancer drug, Ibrance, retails at about $12,000 for a supply of 21 capsules, which is astronomical. Thankfully I have a grant that covers my costs at this time and so I am able to take the drug. I have had to fight for my medication and the process is ridiculously long and tiring. Patients shouldn’t have to go through the stress of trying to get the medication they need to survive. Ibrance’s price tag makes this therapy unaffordable for countless Americans, and Pfizer must stop their price gouging or patients will continue to suffer.